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Abstract: In the US, an estimated 1 million people are infected with HIV, although one-third 
of this population are unaware of their diagnosis. While HIV infection is commonly thought to 
affect younger adults, there are an increasing number of patients over 50 years of age living with 
the condition. UNAIDS and WHO estimate that of the 40 million people living with HIV/AIDS 
in the world, approximately 2.8 million are 50 years and older. With the introduction of highly 
active antiretroviral therapy (HAART) in the mid-1990s, survival following HIV diagnosis 
has risen dramatically and HIV infection has evolved from an acute disease process to being 
managed as a chronic medical condition. As treated HIV-infected patients live longer and the 
number of new HIV diagnoses in older patients rise, clinicians need to be aware of these trends 
and become familiar with the management of HIV infection in the older patient. This article is 
intended for the general clinician, including geriatricians, and will review epidemiologic data 
and HIV treatment as well as provide a discussion on medical management issues affecting 
the older HIV-infected patient.
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General HIV disease process
Human immunodeﬁ  ciency virus type 1 (HIV-1) is an enveloped retrovirus belonging 
to the group of viruses known as lentiviruses. Transmission of HIV occurs when the 
virus enters the blood stream by direct contact or penetration of mucosal surfaces. 
Infection of human cells begins with the attachment of HIV to CD4 and other co-
receptors such as CCR5 and CXCR4 on the surface of the cell. Once inside the cell, 
viral RNA is transcribed to DNA by the HIV reverse transcriptase. Viral DNA then 
integrates into the host cell genome and uses host cell mechanisms to produce viral 
progeny. HIV speciﬁ  cally targets and infects CD4+ cells, which includes T-helper 
lymphocytes and other mononuclear cells, ultimately leading to the destruction of 
these important mediators of the immune system.
Acute HIV infection can manifest as a nonspeciﬁ  c viral illness often described 
as ﬂ  u- or mono-like symptoms which can include: fever, rash, lymphadenopathy, 
pharyngitis, myalgias, and malaise. Symptoms commonly persist for approximately 2 
weeks, although they may last for several weeks in certain cases, and will resolve even 
without treatment. Development of HIV antibodies or seroconversion generally occurs 
between 3 to 6 weeks following initial infection. For the majority of the HIV-infected 
population, the intermediate period of chronic (or latent) HIV infection that follows 
the acute HIV syndrome can range from 10 to 15 years. Here, the individual remains 
generally asymptomatic, given that the immune system is still able to function and keep 
ongoing HIV replication under relative control. Over time, the continued destruction 
of CD4 cells by HIV progresses to the late stage of HIV infection known as acquired 
immunodeﬁ  ciency syndrome or AIDS. AIDS is deﬁ  ned by a CD4 count  200 cell/mm3, 
CD4 percent  14%, or the presence of an opportunistic infection or HIV-associated 
malignancy (CDC 1992). Without HIV treatment, most HIV-infected persons with Clinical Interventions in Aging 2008:3(3) 454
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AIDS develop AIDS complications or death within 2–3 
years, if not sooner.
Effects of aging and HIV infection 
on the immune system
The thymus is an important organ involved in the develop-
ment of the human immune system and serves as the primary 
location for T lymphocyte maturation. T lymphocytes are 
genetically diverse, and function as naïve T cells responding 
to new antigenic exposures or as memory T cells responding 
to antigens the body has previously been exposed to. In partic-
ular, the activation of CD4+ T-helper cells triggers an immune 
response through T cell differentiation and proliferation; 
activation of B cells resulting in antibody development and 
secretion; stimulation of other effector cells, such as CD8+ 
cytotoxic T cells and macrophages, through cytokine release; 
and/or delayed-type hypersensitivity.
As a person ages, involution of the thymus occurs, and 
resultant thymic volumes are signiﬁ  cantly lower in per-
sons 45 years and older as compared to younger persons 
(Kalayjian et al 2003). Moreover, the production of naïve 
T cells declines with increasing age and thymic output is 
only minimal after age 55 (Naylor et al 2005). Increased age 
is further associated with diminished T cell functionality, 
reduced memory T cell populations, and fewer numbers of 
properly functioning CD8+ cytotoxic T cells (Effros 2004). 
These factors may explain why elderly persons are more 
prone to new infections, demonstrate less than optimal 
response to immunizations, or manifest anergy to skin tests 
such as with puriﬁ  ed protein derivative (PPD).
In addition, thymic function and production of naïve 
T cells may be inhibited by HIV infection (Douek et al 1998). 
Because these changes in the immune system are very similar 
to aging effects, progression of HIV infection in the elderly 
may be more pronounced. Not only are CD4 cell counts sig-
niﬁ  cantly lower in HIV-infected young and older adults when 
compared to their age-matched controls, but HIV-infected 
older subjects have the lowest counts (Kalayjian et al 2003). 
In both HIV-infected and non-HIV-infected older subjects, the 
proportion of functional CD8+ T cells was lower compared 
to the younger subjects, but HIV-infected older subjects 
appeared to be impacted most by having the lowest proportion 
among the four comparison groups. Since CD8+ cytotoxic 
T cells are important in the containment of HIV replication, 
reduction in their number and functionality associated with 
HIV infection and aging, coupled with loss of CD4 cells, may 
help explain the accelerated progression of HIV infection in 
older adults. Finally, changes in T-cell receptor expression 
as a person ages, such as increased expression of the CCR5 
co-receptor, is important in the pathogenesis of HIV infec-
tion and could also inﬂ  uence disease progression (Kalayjian 
et al 2003; Yung and Mo 2003). Thus, HIV infection can 
compound, or be synergistic with, the effects of aging on 
the human immune system.
Studies have demonstrated that age is an independent 
predictor of clinical progression in HIV. In a study evaluating 
the prognosis of HIV infection in treatment-naïve patients 
starting on HAART, Egger and colleagues (2002) identiﬁ  ed 
age 50 years and older as an independent prognostic factor 
affecting clinical progression to AIDS or death. A retrospec-
tive case-control study conducted by Butt and colleagues 
(2001) revealed that age 60 years and older at time of HIV 
diagnosis was associated with shorter survival periods. 
Similarly, in their analysis of data from two large published 
HIV data sets, Babiker and colleagues (2001) determined 
that increasing age at time of seroconversion was associated 
with lower survival rates among HIV-infected patients, par-
ticularly in the years prior to the use of HAART. Adjusted 
for general aging effects on mortality, the median survival 
for those who were infected at ages 25 to 34 years old was 
11 years, as compared to 6.6 years and 4.4 years in those 
who were infected at 55 to 64 years old and 65 years and 
older, respectively. The investigators also found that for 
every 10-year increase in age at time of HIV infection, the 
overall mortality rate increased by 43%. Aside from age at 
infection, the time since infection was positively correlated 
with increased mortality in older persons (ages 45 to 55 years 
old) who had the highest death rate as compared to younger 
persons less than 45 years old. Rapid progression to AIDS 
and decreased survival in older HIV-infected patients has 
also been conﬁ  rmed in French and Spanish cohorts (Grabar 
et al 2004; Nogueras et al 2006).
Epidemiology
UNAIDS and WHO estimate that of the 40 million people 
living with HIV/AIDS in the world, approximately 2.8 mil-
lion are 50 years and older. Data from industrialized coun-
tries and as reported by UNAIDS primarily reﬂ  ects the HIV 
epidemic up to the age of 49 years. However, some data in 
the elderly have been reported. As of June 2006, 8% of HIV 
cases (12% of these are women) and 12% of AIDS patients 
were 50 years or older in Canada (Public Health Agency of 
Canada 2006). Of AIDS cases reported in 2006 in Australia, 
people over the age of 50 years accounted for 14% of AIDS 
cases (over 90% men) and 17% of deaths (National Centre 
in HIV Epidemiology and Clinical Research 2007). As of Clinical Interventions in Aging 2008:3(3) 455
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2007 in the United Kingdom, 8.5% and 3.8% of HIV cases 
were diagnosed in men and women over the age of 50 years 
respectively (HPA Communicable Disease Surveillance 
Center 2007).
In the US, approximately one million people are infected 
with HIV, although an estimated one-quarter to one-third 
does not know of their HIV infection. It is also estimated that 
about 40,000 new HIV infections occur every year. Of new 
HIV/AIDS cases reported to the Centers for Disease Control 
and Prevention (CDC) in 2005, over 15% were in persons 
50 years and older while nearly 2% of new diagnoses were 
in patients over 65 years of age (CDC 2006).
While 50 years of age is not generally used to identify 
“elderly” patients, this age cut-off is frequently used by the 
CDC in HIV/AIDS statistics, since this is much older than the 
average age (~30 years old) of the typical US HIV-infected 
person. Between 2001 and 2005, the estimated number of 
AIDS cases by age of diagnosis had risen by nearly 40% in 
persons 50 years and older (CDC 2006). During the same 
time period, the number of persons 50 years and older living 
with AIDS had doubled, and by the end of 2005, this age 
group represented close to 30% of the total US population 
living with AIDS.
The CDC HIV/AIDS Surveillance Report reveals other 
interesting trends among the older HIV population. Survival 
after HIV/AIDS diagnosis in older patients is reduced: only 
60% versus 80% survival in HIV-infected adults aged 25 
(CDC 2006). Survival beyond 12 months after an AIDS 
diagnosis also decreased as age at diagnosis increased among 
persons at least 35 years old, with the lowest survival rate 
among those over 65 years old. Between 2001 and 2005, 
the estimated number of deaths among persons with AIDS 
increased in those 45 years and older, with a 28% increase 
in persons 50 years and older and 18% increase in persons 
60 years and older.
The rise in overall number of persons 50 years and older 
newly diagnosed with HIV or living with HIV/AIDS may be 
a result of late diagnosis or due to the effectiveness of potent 
therapy currently available to treat HIV infection. These fac-
tors are further discussed in the next sections.
HIV risk behaviors
HIV is transmitted through sexual contact (commonly men-
who-have-sex-with-men (MSM) or heterosexual), blood 
contact (eg, intravenous drug use (IDU), needle stick, or 
blood transfusion), and perinatally from mother-to-child. 
Risk factors for persons 50 years and older at time of HIV 
diagnosis have changed. Prior to blood supply screening, 
blood transfusion was the primary route of transmission for 
this age group. Currently, MSM and IDU make up approxi-
mately 50% of risk factors associated with HIV infection in 
the older population. Among MSM in the US, from 2001 to 
2004, HIV diagnosis increased in those 45 to 49 years old by 
3.1% and by 6.2% in persons 50 to 54 years old (Hall 2007). 
Nevertheless, heterosexual contact (currently accounting 
for close to 10% of HIV infection in older adults) is also 
on the rise, predominately affecting women and minority 
groups. In older women, more than 50% of HIV infections 
are reported to be due to heterosexual transmission while IDU 
is much lower (nearly 15%). Among heterosexually-acquired 
HIV/AIDS cases reported to the CDC between 1999 and 
2004, 19% and 12% were men and women 50 years and older 
respectively (Espinoza et al 2007). In addition, the estimated 
annual percentage change in heterosexually-acquired HIV/
AIDS cases rose signiﬁ  cantly among men 50–59 years old 
(+4.9%) and women 50–59 years old (+6.8%) and women 
60 years and older (+4.1%). Concurrent diagnoses of HIV 
and AIDS was slightly higher in non-Hispanic White and 
Hispanics compared to non-Hispanic Blacks. However, this 
was increased for both genders, regardless of increasing age 
(Espinoza et al 2007).
Early in the US HIV epidemic, the National AIDS 
Behavior Survey found that in respondents 50 years and 
older who reported at least one HIV risk behavior there was 
a very low rate of condom use ( 85% reported never using 
or had inconsistent use of condoms during sexual activity). 
In addition, more than 90% of respondents over 50 years old 
had never had an HIV test performed. In contrast, among the 
small subset of gay/bisexual men 50 years and older who 
reported at least one HIV risk behavior, 60% had been tested 
for HIV, and only 9% reported never using condoms while 
52% reported always using condoms during sexual activ-
ity (Stall and Catania 1994). This data suggests that older 
adults who have at least one HIV risk factor are less likely 
to assume behaviors, such as condom use, that can prevent 
the transmission of HIV.
In a recent review of HIV risk factors in the elderly, 
older adults were found to engage in a variety of sexual 
activities, although older men reportedly were more sexually 
active than older women. A large majority of older women 
lacked knowledge of personal risk and/or had not engaged 
in protection behaviors. Although married older women 
were more sexually active than unmarried older women, 
women who had partners and minority women were less 
likely to use a barrier contraceptive method. Condom use 
among women appears to decrease with age, perhaps related Clinical Interventions in Aging 2008:3(3) 456
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to not being concerned about pregnancy or the perception of 
not being at risk for sexually transmitted diseases (STDs). 
Some potential barriers to condom use include difﬁ  culties 
in communication between partners, concern for lack of 
trust, and feelings that the male partner controls condom use 
(Zablotsky and Kennedy 2003). Other factors which might 
increase the risk of HIV transmission among older women 
can include changing sexual relationships due to divorce or 
death and menopausal changes in vaginal mucosa increas-
ing the likelihood for trauma and STDs (Shah and Mildvan 
2006). Although drugs used to treat erectile dysfunction 
in older men have not been shown to result in increased 
HIV transmission in one study, this remains a possibility 
(Karlovsky et al 2004; Shah and Mildvan 2006).
An increased number of newly reported infections in the 
older adult may be due to late HIV testing. The majority of 
cases are not acute infection, but rather chronic, long standing 
HIV infection. Factors associated with late or missed diag-
nosis of HIV infection in older people include: routine HIV 
screening being uncommon in this age group; poor awareness 
of HIV risk factors (including safe sex practices); failure of 
health care providers to consider HIV infection in this patient 
population; and confusion about HIV-speciﬁ  c or opportunistic 
infection (OI) symptoms with symptoms of other diseases fre-
quently associated with older age (eg, Alzheimer’s, dementia) 
(CDC 1998; Mack and Ory 2003; Grabar et al 2006). Thus, 
HIV should be considered in sexually active older persons, 
even if they report being monogamous.
Currently, complete sexual histories may not be routinely 
obtained from older patients by practitioners as a result of dis-
comfort regarding their own sexuality, the sexual orientation 
of the patient, or the lack of recognition that continued sexual 
activity is important in overall wellness of patients. In addi-
tion, older patients may not be comfortable with disclosing 
information that they feel they should be discrete about.
HIV testing
HIV testing in the older adult usually includes an enzyme 
immunoassay (EIA) screening test to detect HIV antibodies 
followed by a conﬁ  rmatory test such as a Western blot or 
immunoﬂ  uorescence assay (IFA) if the screening test is 
positive. Rapid tests, utilizing blood samples or oral secre-
tions, can yield results in as little as 30 minutes and can be 
performed in the clinic or ofﬁ  ce with minimal equipment or 
training. Positive rapid test results should still be conﬁ  rmed 
with a conﬁ  rmatory test. HIV viral load tests (which detect 
HIV RNA in blood plasma) are not usually recommended for 
the diagnosis of HIV infection because of lower speciﬁ  city 
and therefore higher chance for false positive results, 
although the test may be useful in detecting acute HIV 
infection in the right clinical context when seroconversion 
has not yet occurred.
In a study of hospitalized patients who were 60 years 
and older at time of death and had no history of HIV or 
AIDS, 6.2% of men and 8.9% of women were found to be 
HIV-seropositive, and more than 60% of those patients who 
tested HIV-positive had no documented or identiﬁ  able risk 
factors for HIV (el-Sadr and Gettler 1995). In the CDC 2006 
National Health Interview Survey, adults 65 years and older 
had the lowest HIV testing rates (only 11.4% had ever had 
an HIV test) compared to other age groups (the highest rate 
being 53.5% among adults 25 to 34 years old) (CDC 2007). 
Factors which might hinder older adults from seeking an 
HIV test include misconceptions about HIV infection and 
who it affects, denial of risk factors, sense of hopelessness 
even if HIV-positive status was known, and active drug use 
(Lekas et al 2005).
The CDC has recently revised their guidelines for routine 
testing for HIV infection. Written informed consent, as well 
as pre- and post-test counseling is required in most jurisdic-
tions. Current CDC HIV testing guidelines suggest routine, 
voluntary HIV screening in all persons age 13–64 yrs old in 
health care settings, regardless of risk; repeat HIV screening 
at least annually in persons with known risk factors; and opt-
out HIV screening with the opportunity to ask questions and 
the option to decline testing (Branson et al 2006).
Since many patients over the age of 65 years are sexually 
active they should be tested at least once. Our group has also 
recently determined that one time HIV testing is cost-effective 
in those people over the age of 65, particularly if they are 
sexually active (Sanders et al in press). It is also important to 
consider periodic testing in persons with continued risk. If a 
person is found to be HIV-positive, they should be counseled 
to notify their sexual partner (or injecting partner, if applicable) 
and to encourage the partner to be tested for HIV. Requirements 
for partner notiﬁ  cation when HIV infection is diagnosed varies 
by state law, and in some jurisdictions, health care providers 
may be able to notify partners regarding possible exposure to 
HIV even without the HIV-infected person’s consent. Once HIV 
infection has been established, it is important for providers to 
continually encourage and discuss risk and harm reduction as 
well as safe sex practices with their patients.
HIV treatment
Antiretroviral (ARV) therapy in HIV treatment is made up 
of a combination regimen, usually including a minimum of Clinical Interventions in Aging 2008:3(3) 457
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3 different ARV agents, preferably from at least two different 
classes. Currently, there are 6 classes of antiretroviral agents 
available (Table 1): nucleoside reverse transcriptase inhibitors 
(NRTIs) block the viral RNA to DNA transcription process 
by substituting in chain-terminating nucleosides (or nucleo-
tides) in the DNA chain; nonnucleoside reverse transcriptase 
inhibitors (NNRTIs) change the conformation of the reverse 
transcriptase enzyme, rendering the enzyme dysfunctional; 
protease inhibitors (PIs) inhibit the protease enzyme which 
cleaves viral proteins into functional components prior to 
packaging into new HIV particles; fusion inhibitors which 
block the fusion of HIV with the host cell at the initial point 
of contact preventing HIV infection; entry inhibitors which 
block the entry of HIV into the host cell by blocking the cell-
surface co-receptor CCR5; and integrase inhibitors prevent 
the integration of the viral DNA into the host genome. At this 
time, available data regarding fusion, entry, and integrase 
inhibitors have reserved usage of these agents to “salvage 
therapy”, where HIV-infected patients have limited treatment 
options available due to signiﬁ  cant viral resistance.
Combination therapy for HIV infection is required as the 
virus can develop resistance quickly to one agent if given as 
monotherapy. HIV replicates at high levels producing billions 
of copies per day. Since the HIV reverse transcriptase does not 
necessarily produce copies that are completely the same as the 
parent strain, mutations are created, some of which can result 
in ARV drug resistance. In the presence of less potent ARV 
therapy, viral replication continues unabated in the presence of 
ARV drugs, allowing viral strains containing drug-associated 
mutations to outcompete parent strains without these muta-
tions. With combination regimens, it takes the virus much 
longer to develop resistance to the entire regimen, if at all.
Table 1 Antiretroviral agents for treatment of HIV infection
Drug class  Available agents generic (common abbreviation) – alphabetic order
Nucleoside reverse transcriptase   Abacavir (ABC)
inhibitor   Didanosine (ddI)
(NRTI) Emtricitabine  (FTC)
 Lamivudine  (3TC)
 Stavudine  (d4T)
 Tenofovir  (TDF)
  Zidovudine (AZT or ZVD)
Nonnucleoside reverse   Delavirdine (DLV)
transcriptase inhibitor  Efavirenz (EFV)
(NNRTI) Etravirine  (ETR)
 Nevirapine  (NVP)
Protease inhibitor  Atazanavir (ATV)
(PI) Darunavir  (DRV)
 Fosamprenavir  (FPV)
 Indinavir  (IDV)
 Nelﬁ  navir (NFV)
 Ritonavir  (RTV)
 Saquinavir  (SQV)
 Tipranavir  (TPV)
Fusion inhibitor  Enfuvirtide (T-20)
Entry inhibitor  Maraviroc (MVC; Selzentry™; Pﬁ  zer Inc., New York, NY, USA)
Integrase inhibitor  Raltegravir (RAL; Isentress™; Merck and Co., Inc., Whitehouse Station, NJ, USA)
Combination agents – NRTIs
Lamivudine/Zidovudine (Combivir®; GlaxoSmithKline, Research Triangle Park, NC, USA)
Abacavir/Lamivudine (Epzicom®; GlaxoSmithKline, Research Triangle Park, NC, USA)
Tenofovir/Emtricitabine (Truvada®; Gilead Sciences, Inc., Foster City, CA, USA)
Abacavir/ Lamivudine/Zidovudine (Trizivir®; GlaxoSmithKline, Research Triangle Park, NC, USA)
Combination agents – NNRTI + 2 NRTIs
Efavirenz/Emtricitabine/Tenofovir (Atripla®; Bristol-Myers Squibb and Gilead Sciences, LLC, Foster City, CA, USA)
Combination agents – PIs
Lopinavir/Ritonavir (common abbreviation: LPV/r) (Kaletra®; Abbott Laboratories, North Chicago, IL, USA)Clinical Interventions in Aging 2008:3(3) 458
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Treatment guidelines are available for the management of 
ARV therapy naïve patients from the US Department of Human 
and Health Services (DHHS 2008) and the International AIDS 
Society-USA (IAS-USA) collaborative (Hammer et al 2006) 
(Table 2), as well as other expert panels from Europe and 
Australia. Based on evidence from clinical trials and expert 
opinion, current treatment guidelines have established preferred 
recommended regimens that include 1 NNRTI + 2 NRTIs or 
1 PI + 2 NRTIs. Alternate regimens are also provided in the 
guidelines for select cases where certain ARV drug classes are 
contraindicated because of drug interactions, ARV resistance, 
or severe intolerability to preferred regimens.
The decision to start ARV treatment requires the 
assessment of several factors including medical necessity, 
psychological readiness, sociologic stability, and cultural 
factors. Guidelines have been established as to when ARV 
treatment should be initiated based on the CD4 count. In 
general, ARV treatment should be recommended to anyone 
with an AIDS-deﬁ  ning illness, HIV-associated nephropathy, 
or a CD4 count  350 cells/mm3 regardless of viral load level. 
In those with a CD4 count  350 cells/mm3, ARV treatment 
can be considered based on an assessment of potential risks 
(eg, drug toxicities) and beneﬁ  ts (eg, slow down disease 
progression) of therapy.
Because of the development of ARV resistance, poor 
medication adherence, and medication toxicities, antiret-
roviral regimens do fail. In treatment-experienced patients, 
other combination ARV regimens to which their viral strain 
is not resistant as determined by resistance testing are then 
prescribed. When viral resistance is present, it is important 
to utilize at least 2 new active antiretrovirals, since the addi-
tion of a single active antiretroviral to a failing regimen can 
quickly result in viral resistance to the newly added agent. 
Ultimately, multi-drug resistance limits treatment options 
signiﬁ  cantly. Although the current US DHHS (2008) guide-
lines address management of drug-resistant HIV in treatment-
experienced patients, the guidelines panel acknowledges that 
there is no consensus on speciﬁ  c treatment strategies and that 
treatment of these patients are often complex. Therefore, 
HIV treatment of such patients is usually undertaken by 
experienced HIV practitioners based on emerging data and 
clinical HIV expertise and is still evolving.
Whether on or off antiretroviral therapy, as CD4 cell 
counts decline, patients become more prone to opportunis-
tic infections such as Pneumocystis pneumonia (PCP) and 
malignancies such as non-Hodgkin’s lymphoma. Opportu-
nistic infections (OI) in HIV/AIDS account for signiﬁ  cant 
morbidity and mortality in this patient population. Although 
Table 2 Preferred initial treatment regimens recommended for HIV-treatment-naïve adult patients based on adult HIV treatment 
guidelines from US DHHSa and IAS-USAb
Preferred base  US DHHS  IAS-USA
NNRTI-Based  Efavirenz  Efavirenz OR Nevirapine
 PLUS  PLUS
 Tenofovir/Emtricitabine  Tenofovir/Emtricitabine
 OR  OR
 Abacavir/Lamivudine  Zidovudine/Lamivudine
   OR
   Abacavir/Lamivudine
PI-Based, Ritonavir boosted  Lopinavir/Ritonavir  Lopinavir/Ritonavir
 OR  OR
 Atazanavir/Ritonavir  Atazanavir/Ritonavir
 OR  OR
 Fosamprenavir/Ritonavir  Fosamprenavir/Ritonavir
 PLUS  PLUS
 Tenofovir/Emtricitabine  Tenofovir/Emtricitabine
 OR  OR
 Abacavir/Lamivudine  Zidovudine/Lamivudine
   OR
   Abacavir/Lamivudine
Abbreviations: DHHS, Department of Health and Human Services; IAS, International AIDS Society; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease 
inhibitor.
aDepartment of Health and Human Services: Panel on Antiretroviral Guidelines for Adults and Adolescents 2008; bHammer et al 2006.Clinical Interventions in Aging 2008:3(3) 459
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antiretroviral therapy has signiﬁ  cantly reduced the incidence 
of OIs and improved survival in HIV infection, just receiving 
ARV therapy does not preclude the need for OI prophy-
laxis in patients with continued severe immunosuppression 
(eg, CD4 count  200/mm3). Even without ARV therapy, 
OI prophylaxis can delay presentation of ﬁ  rst AIDS-related 
illness. Patients who develop an OI and have continued 
immunosuppression below a CD4 count of 200/mm3 after 
successful treatment still require secondary prophylaxis to 
prevent recurrence. In those patients in whom ARV treat-
ment has resulted in signiﬁ  cant increases in CD4 count above 
200/mm3, most OI prophylaxis can be safely discontinued 
in the majority of patients. Guidelines jointly developed by 
the US Public Health Service and the Infectious Diseases 
Society of America are available to assist with identifying 
when certain OI prophylaxis are indicated, based primar-
ily on CD4 cell count and are summarized in Table 3a and 
Table 3b (CDC 2002).
HIV treatment in older patients
There are no speciﬁ  c treatment guidelines currently avail-
able that focus on management in the older HIV-infected 
adult. Additionally, there is limited information on the efﬁ  -
cacy and safety of selected antiretroviral regimens for older 
patients. Even with the initiation of antiretroviral therapy, 
CD4 cell recovery may be limited in elderly HIV-infected 
patients. In one study of 3,015 HIV-infected patients, of 
whom 13% were 50 years and older, the mean CD4 cell 
counts rose signiﬁ  cantly within the ﬁ  rst six months of ARV 
therapy; however, mean CD4 cell count increases were 
signiﬁ  cantly higher in younger patients as compared to older 
patients when stratiﬁ  ed by baseline HIV viral load and CD4 
cell counts (Grabar et al 2004). Prior to this study, Manfredi 
and Chiodo (2000) had demonstrated similar results where 
patients 55 years and older showed a signiﬁ  cantly blunted 
CD4 cell count response compared to the response seen in 
patients 35 years and younger. A more recent study showed 
that initial CD4 cell count response in older patients was 
slower during the initial phase of HAART therapy, but 
after 3 years of ARV therapy, the CD4 cell counts were 
not signiﬁ  cantly different from that of younger patients 
(Silverberg et al 2007).
Limited CD4 cell recovery in elderly HIV-infected patients 
may be due to age-associated decrease in thymic function and 
therefore slower response (Douek et al 1998), or possibly as 
a result of having lower CD4 cell counts at baseline (Grabar 
et al 2004; Nogueras et al 2006). In contrast, there are some 
studies suggesting that CD4 cell count rises and virologic 
responses are not dissimilar between older and younger HIV-
infected patients (Wellons et al 2002; Tumbarello et al 2004). 
Table 3a Recommendations for primary prophylaxis of opportunistic infections in HIV-infected individuals based on CD4 cell count 
(CDC 2002)
CD4 cell count  Opportunistic  Recommended primary  When primary prophylaxis
(cells/mm3)  infection  prophylactic therapy  can be discontinued
 200 Pneumocystis  pneumonia  DOC:  TMP/SMX  CD4    200 cells/ mm3 for at least
  (PCP)  Alternatives:  3 consecutive months
   • Dapsone 
   • Dapsone  + Pyrimethamine 
     ( + Leucovorin) 
   • Pentamidine,  aerosolized 
   • Atovaquone 
 100 Toxoplasmosisa DOC:  TMP/SMX  CD4   200 cells/ mm3 for at least
    Alternatives:  3 consecutive months
   • Dapsone  + Pyrimethamine 
     ( + Leucovorin) 
   • Atovaquone 
     ( +/− Pyrimethamine, 
     + Leucovorin) 
 50  Mycobacterium avium   DOC: Azithromycin or Clarithromycin  CD4  100 cells/ mm3 for at least
  complex (MAC)  Alternatives:  3 consecutive months
   • Rifabutin 
   • Azithromycin + Rifabutin
Abbreviations: DOC, drug of choice;   TMP/SMX, trimethoprim/sulfamethoxazole.
Notes: aPrimary prophylaxis for toxoplasmosis is indicated when CD4 cell count is less than 100 cells/mm3 and patient is toxoplasmosis immunoglobulin G (IgG) antibody 
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In yet other studies, older patients tended to achieve better 
virologic control compared to younger patients, possibly due 
to better medication adherence (Paredes et al 2000; Grabar 
et al 2004; Silverberg et al 2007).
Whether the HIV-infected elderly are at higher risk for 
adverse side effects from antiretroviral therapy is less well doc-
umented. Medication side effects in general tend to be higher in 
older patients (Bowman et al 1996), and may be related to age-
associated declines in hepatic and renal function. Hepatic mass, 
blood ﬂ  ow, and metabolism (via Cytochrome P450 enzyme 
amount and function) are decreased with age (Sotaniemi et al 
1997). In addition, aging-related decrease in renal mass, blood 
ﬂ  ow, tubular secretion, and glomerular ﬁ  ltration (Ramsay and 
Tucker 1981) can lead to drug accumulation and result in drug 
toxicity. Other factors such as polypharmacy can further con-
tribute to increased adverse events (Bowman et al 1996). HIV 
can decrease renal function by speciﬁ  cally infecting the kidney 
leading to a condition known as HIV-associated nephropathy 
(HIVAN) (Herman and Klotman 2003). HIVAN is more likely 
to occur in those who are Black, have AIDS, and are not on 
ARV treatment (Lucas et al 2004).
Age-related changes in body composition can also 
inﬂ  uence drug pharmacokinetics by altering drug volume 
of distribution (Ramsay and Tucker 1981; Bressler and Bahl 
2003). Decreases in body weight and in total body water can 
lead to more concentrated drug levels in blood and tissues, 
and can result in enhanced drug effects and toxicity. On 
the other hand, increases in body fat, which acts as a depot 
for lipid soluble drugs, can result in decreased serum drug 
concentrations and may initially lower drug effects. With 
repeated dosing and time, accumulation of lipid-soluble 
drugs in body fat can lead to toxicity. Slower gastroin-
testinal absorption rate may lead to delayed onset of drug 
effects. Drugs that are highly-protein bound may produce 
Table 3b Opportunistic infections for which secondary prophylaxis is recommended (CDC 2002)
Opportunistic infection  Recommended secondary   When secondary prophylaxis 
  prophylactic therapy  can be discontinued
Pneumocystis pneumonia (PCP)  DOC: TMP/SMX  CD4  200 cells/mm3 for at least 
    3 consecutive months
 Alternatives:
  • Dapsone 
  • Dapsone  + Pyrimethamine 
   ( + Leucovorin) 
  • Pentamidine,  aerosolized 
  • Atovaquone 
Toxoplasmosis DOC:  Sulfadiazine  + Pyrimethamine + CD4   200 cells/mm3 for at least  
  Leucovorin  6 consecutive months, completed
    initial therapy, and asymptomatic
 Alternatives: 
  • Clindamycin  + Pyrimethamine + 
   Leucovorin 
  • Atovaquone + Pyrimethamine + Leucovorin
Disseminated Mycobacterium avium   DOC: Clarithromycin + Ethambutol  CD4  100 cells/mm3 for at least
complex (MAC)  (± Rifabutin)  6 consecutive months, completed 12 months
    of treatment, and asymptomatic
 Alternatives:
  • Azithromycin + Ethambutol (± Rifabutin) 
Cytomegalovirus (CMV) infection  DOC: Ganciclovir  CD4  100–150 cells/mm3 for at least 
    6 consecutive months and no active disease
 Alternatives: 
  • Valganciclovir 
  • Foscarnet 
  • Cidofovir 
Cryptococcosis DOC:  Fluconazole  CD4   100–200 cells/mm3 for at least 
    6 consecutive months, complete initial 
    treatment, and asymptomatic
 Alternatives: 
  • Itraconazole Clinical Interventions in Aging 2008:3(3) 461
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enhanced effects as a person ages and protein concentrations 
decline. Receptor and drug transporter genotype (eg, 
P-glycoprotein, P-gp or MDR1) can also profoundly affect 
drug concentrations and resultant ARV responses (Evans 
and McLeod 2003). Alteration in P-gp or cytochrome 
production or function in the elderly could possibly lead to 
altered responses to drugs (Bressler and Bahl 2003; Kinirons 
and O'Mahony 2004).
Common and notable adverse effects of ARVs are listed 
in Table 4 and are also reviewed in detail elsewhere (Carr 
and Cooper 2000; Manfredi 2002; DHHS 2008). Gastroin-
testinal side effects, such as nausea and vomiting as well as 
diarrhea, are common with nearly all of the antiretroviral 
therapies currently available. Since Efavirenz frequently 
exerts central nervous system effects, caution is advised 
when used in elderly patients who have dementia or other 
underlying psychiatric or cognitive disorder. Tenofovir is 
associated with renal toxicity and should be used with cau-
tion in patients with reduced renal function. Additionally, all 
ARV agents can potentially cause hepatotoxicity, especially 
NNRTIs and PIs, and may have increased risk for adverse 
hepatic effects in patients with underlying liver disease or 
hepatic insufﬁ  ciency. To further limit toxicity, all NRTIs 
(with the exception of Abacavir) must be dose adjusted in 
renal insufﬁ  ciency. It must be noted that limited data are 
available to provide guidance on speciﬁ  c dosage adjustments 
of other antiretrovirals when used speciﬁ  cally in elderly 
patients with renal and/or hepatic insufﬁ  ciency.
Compared to noninfected persons, HIV-infected patients 
appear to have a higher prevalence of metabolic syndrome 
(Bonfanti et al 2007). HAART therapy has also been impli-
cated in causing a metabolic syndrome characterized by 
decreased glucose tolerance and increased insulin resistance, 
dyslipidemias, elevated blood pressure, and abdominal obe-
sity, conditions which appear to be primarily associated with 
long-term use of HIV protease inhibitors (Carr et al 1999; 
Mulligan et al 2000; Palacios and Santos 2007). These drug-
induced metabolic changes, along with older age, have been 
associated with increased risk for cardiovascular disease and 
myocardial infarction (Friis-Moller et al 2003; Iloeje et al 
2005; Friis-Moller et al 2007).
Limited data to date suggests that older HIV-infected 
patients experience more adverse events (Knobel et al 2001) 
and are at higher risk for lab abnormalities (Silverberg et al 
2007) than younger HIV-infected patients receiving ARV 
therapy. Drug-related adverse events could also be related 
to medication nonadherence. Medication adherence issues 
in HIV-infected elderly will be discussed below.
Drug-drug interaction issues
A number of non-HIV related medications can be affected 
by, or directly affect, HIV medications through drug-drug 
interactions, leading to either signiﬁ  cant toxicity or decreased 
efﬁ  cacy of the target medications. In general, NNRTIs and 
PIs are metabolized in the liver and can induce or inhibit 
hepatic Cytochrome P450 enzymes such as CYP 3A4. There-
fore, practitioners should keep in mind potential interactions 
between ARVs and medications that are predominately sub-
strates of 3A4 when prescribing drug therapy. Examples of 
interacting medications include: Warfarin, calcium channel 
blockers, azole antifungals, benzodiazepines, and anticonvul-
sants. Conversely, drugs that strongly induce CYP 3A4 (eg, 
Rifampin), can signiﬁ  cantly lower levels of most NNRTIs 
and PIs, and thus concurrent administration is contraindi-
cated. Additionally, acid suppressants can alter the absorption 
of certain ARVs (eg, Atazanavir) and result in subtherapeutic 
levels of the ARVs and ultimately regimen failure. Table 5 
provides a summary of drugs where concomitant administra-
tion with ARVs is contraindicated (DHHS 2008). In contrast, 
the addition of low-dose Ritonavir to another protease inhibi-
tor (a practice commonly referred to as “boosting”) provides 
a favorable pharmacokinetic interaction resulting in increased 
efﬁ  cacy of the target protease inhibitor. Current HIV treat-
ment guidelines recommend Ritonavir boosting as part of 
the protease inhibitor-based therapies for treatment-naïve 
patients (DHHS 2008; Hammer et al 2006).
Co-morbid disease states
Between 1996 and 2000, rates of hospitalization among 
HIV-infected patients 50 years and over increased while 
hospitalization rates for those 18 to 30 years old decreased 
dramatically (Gebo et al 2005). However, reasons for hospi-
talizations among HIV-infected patients 50 years and older 
has also changed since the introduction of HAART, with 
fewer hospitalizations for OIs, but more hospitalizations 
related to cerebrovascular and ischemic heart diseases. 
Additionally, older age was associated with higher rates of 
hospitalizations for liver-related diseases, pneumonia, and 
diabetes, and higher odds of death during hospitalization 
compared to younger ages.
Heart disease, diabetes, and cancers are among the 
most prevalent chronic medical conditions affecting older 
adults and account for some of the leading causes of death 
in the US population age 65 years and older (FIARS 2006). 
Other conditions such as hypertension, hyperlipidemia, 
cerebrovascular diseases, and declining renal function 
also become more prevalent as a person ages. Even among Clinical Interventions in Aging 2008:3(3) 462
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Table 4 Common and/or important adverse effects associated with currently available antiretroviral therapy (Manfredi 2002; Cooper et al 2007; 
Isentress Pl 2007; Lalezari et al 2007; Nelson et al 2007; Selzentry PI 2007; Steigbigel et al 2007; DHHS 2008; Intelence PI 2008)
Antiretroviral drug class Antiretroviral agent Common and/or important 
adverse effects
Clinical considerations
Nucleoside reverse 
transcriptase inhibitors 
(NRTIs)
Note: All NRTIs have the 
US FDA Black Box Warn-
ing for lactic acidosis and 
severe hepatomegaly with 
steatosis; routine monitor-
ing of lactate levels is not 
recommended, however 
check levels if patient has 
signs or symptoms suspi-
cious for lactic acidosis
Zidovudine •  Nausea, vomiting, headache
•  Anemia (macrocytic), neutropenia
•   Monitor CBC with differential at 
minimum every 3 months (more frequent 
if necessary)
•   Consider EPO for anemia, GCSF for 
neutropenia
Didanosine •  Pancreatitis
•  Peripheral neuropathy
•    Avoid concomitant use with Stavudine, 
Hydroxyurea, or Ribavirin
•    Reduce dose when coadminstered with 
Tenofovir
•    Peripheral neuropathy: avoid other 
neurotoxins, limit EtOH; consider treat 
with Gabapentin, TCAs, Lamotrigine
Stavudine •  Peripheral neuropathy
•  Lipodystrophy (primarily fat wasting)
•  Hyperlipidemia
•    Check for correct weight-based dosing; 
consider dose reduction or switch to 
another agent if symptoms
•    Avoid concomitant use with Didanosine
•    Peripheral neuropathy: avoid other 
neurotoxins, limit EtOH; consider treat 
with Gabapentin, TCAs, Lamotrigine
Lamivudine •    Generally well tolerated
•  Nausea, headache
•   Severe acute exacerbations of HBV 
upon drug discontinuation
•    Closely monitor LFTs in HIV/HBV 
co-infected patients if drug discontinued
Abacavir •   Black Box Warning: Hypersensitivity 
reaction
•  Nausea, vomiting, diarrhea
•   Recommend screen for HLA-B*5701 (an 
MCH class I allele) to determine if patient 
at risk for hypersensitivity reaction; if 
positive, do not start Abacavir
•    Hypersensitivity reaction should be sus-
pected if patient presents with 2 or more of 
the following: fever, rash, GI symptomsa, con-
stitutional symptomsb, respiratory symptomsc
•    If hypersensitivity reaction suspected, 
stop drug immediately and do not 
rechallenge as fatal reactions can occur 
upon re-exposure (includes other 
products containing Abacavir)
Tenofovir •  Nausea, vomiting, diarrhea, ﬂ  atulence
•   Nephrotoxicity (eg, ↑ SCr, 
proteinuria, Fanconi’s syndrome)
•    Severe acute exacerbations of HBV 
upon drug discontinuation
•  Avoid other nephrotoxic drugs
•    Monitor SCr, UA, serum potassium and 
phosphorus (especially in at-risk patients)
•    Closely monitor LFTs in HIV/HBV 
co-infected patients if drug discontinued
Emtricitabine •   Generally well tolerated
•  Nausea, headache
•  Hyperpigmentation of palms, soles
•    Severe acute exacerbations of HBV 
upon drug discontinuation
•    Closely monitor LFTs in HIV/HBV 
co-infected patients if drug discontinued
Nonnucleoside reverse 
transcriptase inhibitors 
(NNRTIs)
Nevirapine •    Black Box Warning: Severe, life-
threatening, and even fatal hepato-
toxicity; skin reactions (including 
Stevens-Johnson Syndrome)
•    Rash, ↑ LFTs
•  Nausea, vomiting, headache
•    Avoid initiating in women with 
CD4  250 cells/mm3, in men with CD4 
 400 cells/mm3
•    Always initiate with a 2-week lead-in 
period with Nevirapine 200 mg once daily
•  Monitor LFTs, skin
Delavirdine •  Rash, ↑ LFTs
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Table 4 (Continued)
Antiretroviral drug class Antiretroviral agent Common and/or important 
adverse effects
Clinical considerations
Efavirenz
Etravirine
•   CNS symptomsd (very common, 
 50%)
•  Rash, ↑ LFTs
•  False-positive cannabinoid tests
• ↑ lipids (including HDL)
•  Rash
•  Nausea
•    Efavirenz should be taken on an empty 
stomach (avoid fatty foods); take before 
bedtime (or 2–3 hours before bedtime)
•    CNS symptoms usually resolve (or 
diminish) after 2–4 weeks of therapy; 
warn patients to limit risky activities until 
effects are known
•    Etravirine should be taken following a 
meal as fasting conditions ↓ absorption 
by 50%
•    Etravirine tablets may be dispersed in 
glass of water if patient unable to swal-
low whole
Protease inhibitors (PIs)
Note: All PIs have been 
associated with GI 
intolerance (nausea, 
vomiting, diarrhea),↑ LFTs, 
hyperglycemia, hyperlip-
idemia (especially hyper-
triglyceridemia), and fat 
maldistrubution; increased 
bleeding episodes may 
be seen in patients with 
hemophilia
Saquinavir •  Headache, fatigue, abdominal pain •   For HIV treatment, Saquinavir should 
only be used combined with Ritonavir 
(in order to attain adequate drug levels)
Indinavir •  Hyperbilirubinemia
•  Nephrolithiasis
•   Hyperbilirubinemia is usually a result 
of ↑ indirect (unconjugated) bilirubin; 
generally asymptomatic, however 
discontinue drug if concurrent ↑ LFTs 
and symptoms
•   Patients should keep hydrated with 
at least 1.5–2 liters/day of ﬂ  uid 
(noncaffeinated preferred) to decrease 
likelihood of nephrolithiasis
Ritonavir •  Perioral parasthesia
•  Taste perversion
•  Asthenia
•    Commonly used in low doses combined 
with other protease inhibitors as a 
pharmacokinetic enhancer (termed 
“boosting”)
Nelﬁ  navir •  Diarrhea (very common, up to 50%) •    Consider preemptive antidiarrheals 
(eg, Loperamide, Diphenoxylate/
Atropine)
•    Calcium tablets, bulk-forming agents (eg, 
Psyllium), and pancreatic enzymes have 
been used anecdotally
Fosamprenavir •    Headache
•  Nausea, vomiting, diarrhea
•  Rash (sulfa moiety)
•    Use with caution, monitor closely in 
patients with sulfonamide allergy
Atazanavir •  Hyperbilirubinemia
•  Nephrolithiasis
•  PR interval prolongation
•    Hyperbilirubinemia is usually a result of ↑ 
indirect (unconjugated) bilirubin; generally 
asymptomatic, however discontinue drug if 
concurrent ↑ LFTs and symptoms
•   Use caution in patients with underlying 
cardiac conduction abnormalities or taking 
other medications that can prolong PR 
interval
Lopinavir/Ritonavir •  Perioral parasthesia, asthenia
• ↑ GGT
•    GI intolerance much more likely with 
once-daily dosing than twice-daily dosing
Tipranavir •    Black Box Warning: Clinical hepatitis 
and hepatic decompensation 
(including fatal reactions)
•    Black Box Warning: Intracranial 
hemorrhage (both fatal and nonfatal) 
have been reported, however causal 
relationship not yet established
•    For HIV treatment, Tipranavir should 
only be used combined with Ritona-
vir (in order to attain adequate drug 
levels)
•    Use contraindicated in patients with 
Child-Pugh class B or C hepatic 
insufﬁ  ciency
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HIV-infected patients, a higher percentage of older patients 
have diabetes, chronic respiratory disorders, hypertension, 
and hyperlipidemia, as well as other cardiac conditions, such 
as coronary heart disease and heart failure (Skiest et al 1996; 
Butt et al 2004; Palacios et al 2006). In one study of HIV-
infected persons 55 years and older, 89% had one or more 
co-morbidities, with an average of 2.4 co-morbid conditions 
per person (Shah et al 2002). Whether any or all of these 
co-morbid conditions can exacerbate the natural history of 
HIV infection in older patients, further compound toxicities 
from HIV therapy, or affect morbidity and mortality in this 
patient population remains to be determined.
There is limited evidence-based literature to guide therapy 
of metabolic complications speciﬁ  cally in HIV-infected 
patients although various groups have developed general 
guidelines to assist the clinician in areas of managing meta-
bolic complications associated with HAART (Schambelan 
et al 2002) and separate guidelines for addressing dyslip-
idemia in HIV (Dube et al 2003). A brief review of these 
recommendations and of current HIV clinical practice is 
provided for the reader under the section titled “Primary 
care issues.”
As mentioned earlier, declining CD4 cell counts in HIV 
infection is associated with increased risk for certain types 
of malignancy. The CDC’s AIDS case deﬁ  nition includes 
Kaposi’s sarcoma (KS), lymphomas, such as Burkitt’s lym-
phoma and non-Hodgkin’s lymphoma (NHL), and invasive 
cervical carcinoma (CDC 1992). Since the introduction 
Table 4 (Continued)
Antiretroviral drug class Antiretroviral agent Common and/or important 
adverse effects
Clinical considerations
•  Rash (sulfa moiety) •   Monitor closely for hepatotoxicity in 
patients co-infected with HBV and/or HCV
•   Use with caution in patients at increased 
risk for bleeding
Darunavir •  Rash (sulfa moiety)
•  Neutropenia
•  Nasopharyngitis
•  Headache
•    For HIV treatment, Darunavir should 
only be used combined with Ritonavir 
(in order to attain adequate drug levels)
•    Use with caution, monitor closely in 
patients with sulfonamide allergy
Fusion inhibitors Enfuvirtide •    Injection site reactionse (very 
common,  90–95%)
•  Bacterial pneumonia
•  Hypersensitivity reaction uncommon
•    Patients should be counseled on sterile 
and administration techniques; rotate 
injection sites
•    Massaging injection area may reduce pain, 
nodules
•    Warm compress, analgesics, 
antihistamines may be used as necessary
Entry inhibitors Maraviroc •   Black Box Warning: Hepatotoxicity 
with allergic-type reaction
(eg, pruritic rash, eosinophilia) have 
been reported
•  Diarrhea, nausea, vomiting
•  Postural hypotension, headache
•    Fever, respiratory symptoms 
(eg, cough, infection)
•    Monitor LFTs, allergic-type reaction 
(allergic-type reaction may preceed 
hepatotoxicity)
Integrase inhibitor Raltegravir •  Diarrhea, nausea
•  Headache
• ↑ Creatine kinase
•    Cancers commonly associated with 
severe immunodeﬁ  ciency were reported 
in clinical trials, however it is unknown 
at this time if this is directly related to 
Raltegravir treatment
•    Caution in patients already at risk for 
myopathy or rhabdomyolysis
Abbreviations: FDA, Food and Drug Administration; ↑, increase; ↓, decrease; CBC, complete blood count; EPO, erythropoietin; GCSF, ﬁ  lgrastim; TCA, tricyclic antidepressant; 
EtOH, alcoholic beverages; SCr, serum creatinine; UA, urinalysis; LFTs, liver function tests; HBV, Hepatitis B virus; HCV, Hepatitis C virus; GGT, Gamma-glutamyl transferase.
Notes: aGastrointestinal (GI) symptoms may include nausea, vomiting, diarrhea, abdominal pain; bConstitutional symptoms may include generalized malaise, fatigue, body aches, 
loss of appetite; cRespiratory symptoms may include dyspnea, cough, pharyngitis; dCentral nervous system (CNS) symptoms may include dizziness, somnolence, insomnia, 
abnormal dreams (eg, nightmares, vivid dreams), confusion, abnormal thinking or difﬁ  culty concentrating, amnesia, agitation, hallucinations, euphoria; eInjection site reactions 
may include pain, erythema, induration, nodules, cysts, pruritis.Clinical Interventions in Aging 2008:3(3) 465
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of HAART, the incidences of KS and NHL among AIDS 
patients have signiﬁ  cantly declined (Clifford et al 2005; 
Engels et al 2006). Nonetheless, regardless of HAART, there 
are other non-AIDS deﬁ  ning malignancies found in a greater 
proportion of HIV-infected patients compared to the general 
population, including lung, liver, brain, and anal cancers (Dal 
Maso et al 2003; Clifford et al 2005; Engels and Goedert 
2005; Engels et al 2006).
Cancer risk also increases with age in non-HIV-infected 
persons, but very limited data is available evaluating the 
impact of HIV infection on cancer risk in older persons and 
vice versa. Using data from the AIDS-Cancer Registry Match 
study, Engels (2001) determined risk for KS and lung cancer 
in AIDS patients stratiﬁ  ed by age. In AIDS patients 60 years 
and older, risk for KS was signiﬁ  cantly lower than that among 
patients 30 to 39 years old. The author noted that this trend 
was quite different from KS previously seen at a higher rate 
in non-HIV infected elderly European and Mediterranean 
men. Conversely, the incidence of lung cancer among AIDS 
patients increased with age from 0.1 per 1,000 persons-years 
in the 15 to 29 years old age group to 3.7 per 1,000 persons-
years in the 60 years and older age group. Even though this 
mirrored the increasing incidence of lung cancer with aging in 
the general population, the overall incidence was still higher 
in AIDS patients than in the age-matched population.
The same study group also sought to determine effects of 
HIV infection on the cancer risk proﬁ  le of AIDS patients 60 
years and older. Compared to the general population, elderly 
AIDS patients had a relative risk of 1.3 for all non-AIDS 
deﬁ  ning cancers (Biggar et al 2004). In this analysis, elderly 
AIDS patients had a higher risk for Hodgkin’s lymphoma, 
anal cancer, liver cancer, and multiple myeloma. Addition-
ally, lung and stomach cancer risks were higher in this group. 
One interesting observation was that prostate cancer was 
negatively associated with AIDS. The authors speculated 
that this may be due to reduced screening in the elderly HIV/
AIDS population. These data demonstrate that information 
on cancer risk in elderly HIV-infected persons is still evolv-
ing, and until more deﬁ  nitive information becomes available, 
the clinician should be aware of and continue screening for 
HIV-associated and age-associated malignancies.
Although many factors are associated with the develop-
ment of osteopenia and osteoporosis, recent studies have sug-
gested that women with HIV infection are at greater risk for 
this condition, which can be further accentuated when taking 
certain ARV regimens (Dolan et al 2004; Pan et al 2006; 
Anastos et al 2007). HIV-infected older men also manifest 
decreased bone mineral density compared to uninfected men 
(Arnsten et al 2007). Whereas some studies have determined 
that HIV infection and lower CD4 counts result in earlier 
onset of menopause (Schoenbaum et al 2005), the effect 
of HIV infection on women’s hormonal levels, menstrual 
cycles and the relationship with resultant osteoporosis is 
not clear. HIV infection and increasing age in men are also 
associated with hypogonadism (Crum-Cianﬂ  one et al 2007). 
A multitude of clinical conditions including sexual dysfunc-
tion, fatigue, poor appetite and osteopenia are associated 
with hypogonadism (Klein et al 2005). Androgen replace-
ment and treatment of erectile dysfunction even in elderly 
men can result in signiﬁ  cant improvements in some of these 
conditions and in quality of life (Crum et al 2005). Practitioners 
should keep in mind that in HIV-infected patients treated with 
protease inhibitors, caution should be used with the concur-
rent administration of phosphodiesterase enzyme inhibitor 
medications for erectile dysfunction (eg, sildenaﬁ  l) due to 
clinically important drug interactions. Protease inhibitors 
can inhibit the metabolism of the erectile dysfunction agent, 
thereby leading to high blood levels and increased risk for 
side effects such as severe hypotension.
Psychiatric disorders may predispose persons to HIV 
risk behaviors and ultimately HIV infection. HIV infection 
itself can also increase the likelihood of active psychiatric 
disorders, including depression, bipolar disorder and mania, 
psychosis, and anxiety disorders as well as cognitive decline, 
dementia, and substance abuse disorders. In their review of 
the literature on psychiatric co-morbidity in HIV-infected 
older patients, Skapik and Treisman (2007) revealed that 
HIV-positive older adults had higher rates of depression 
and poorer cognitive function compared to HIV-negative 
older adults. Furthermore, it is postulated that various psy-
chiatric disorders may contribute to the progression of HIV 
disease through a number of interactions leading to further 
immunosuppression. When managing psychiatric disorders 
in HIV-infected patients, the clinician should keep in mind 
that a number of psychotropics (including, but not limited 
to selective serotonin reuptake inhibitors (SSRIs), benzodi-
azepines, and tricyclic antidepressants) can have signiﬁ  cant 
interactions with antiretroviral therapy and thus dosing titra-
tion is key. In addition, Efavirenz can cause psychiatric and 
neurologic disturbances and should be used with caution; 
patients should be counseled regarding its potential effects. A 
number of review articles summarizing the data and treatment 
considerations on this topic are currently available and the 
reader is referred to these references for further information 
as needed (Hinkin et al 2001; Dolder et al 2004; Skapik and 
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Table 5 Signiﬁ  cant drug–drug interactions that may be seen in the elderly where concomitant use is contraindicateda
Drug Class Cardiovascular 
agents
Lipid lowering 
agents
Anti-
microbials
Anti-
histamines
Gastrointestinal 
agents
CNS agentsb Herbals Other
Antiretrovirals: Nonnucleoside reverse transcriptase inhibitors
Nevirapine – – Rifampin – – – St. John’s Wort –
Rifapentine
Delavirdine – Lovastatin
Simvastatin
Rifampin
Rifapentine
Rifabutin
Astemizole
Terfenadine
Cisapride
H2 blockers
PPI
Alprazolam
Midazolam
Triazolam
St. John’s Wort Amprenavir
Fosamprenavir
Carbamazepine
Ergot alkaloids Phenobarbital
Phenytoin
Efavirenz – – Rifapentine Astemizole Cisapride Midazolam St. John’s Wort Voriconazole
Terfenadine Triazolam
Ergot alkaloids
Etravirine – – Rifampin
Rifapentine
– – – St. John’s Wort Unboosted PIs
Boosted ATV, 
FPV, TPV
Carbamazepine
Phenobarbital
Phenytoin
Antiretrovirals: Protease inhibitors
Saquinavir – Lovastatin Rifampin Astemizole Cisapride Pimozide St. John’s Wort Fluticasone
Simvastatin Rifapentine Terfenadine Midazolam
Rifabutinc Triazolam
Ergot alkaloids
Indinavir Amiodarone Lovastatin Rifampin Astemizole Cisapride Pimozide St. John’s Wort Atazanavir
Simvastatin Rifapentine Terfenadine Midazolam
Triazolam
Ergot alkaloids
Ritonavir Amiodarone Lovastatin Rifapentine Astemizole Cisapride Pimozide St. John’s Wort Voriconazoled
Bepridil Simvastatin Terfenadine Midazolam
Flecanide Triazolam
Propafenone Ergot alkaloids
Quinidine
Nelﬁ  navir – Lovastatin Rifampin Astemizole Cisapride Pimozide St. John’s Wort –
Simvastatin Rifapentine Terfenadine Midazolam
Triazolam
Ergot alkaloids
Fosamprenavir Bepridil Lovastatin Rifampin Astemizole Cisapride Pimozide St. John’s Wort Delavirdine
Simvastatin Rifapentine Terfenadine Midazolam Fluticasone
Triazolam
Ergot alkaloids
Atazanavir Bepridil Lovastatin Rifampin Astemizole Cisapride Pimozide St. John’s Wort Fluticasone
Simvastatin Rifapentine Terfenadine PPI Midazolam Indinavir
Triazolam Irinotecan
Ergot alkaloids
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In advanced immunosuppression, symptoms of opportu-
nistic infections that preferentially infect the central nervous 
system (eg, cryptococcal meningitis and toxoplasma encepha-
litis) may be difﬁ  cult to distinguish from age-related neuro-
logic changes. HIV neurologic syndromes, such as AIDS 
dementia and progressive multifocal leukoencephalopathy 
(PML), can also manifest as or aggravate underlying dementia 
symptoms in the elderly. HIV-associated dementia has been 
found to have higher prevalence and tends to be more severe in 
HIV-infected patients age 50 years and older than in younger 
patients (age 20 to 39 years old) (Valcour et al 2004). In con-
trast, the Veterans Aging Cohort Five-Site Study did not ﬁ  nd 
depression and alcohol/drug abuse to increase with age – in 
fact, just the opposite, when comparing HIV-infected patients 
by age group (Justice et al 2004). What the investigators did 
ﬁ  nd was that HIV-infected patients had higher prevalence of 
depression and alcohol/drug abuse than age-matched non-
HIV-infected patients. Regardless of HIV infection status, 
memory problems were positively correlated with increased 
age in this study population. Thus, the presence of both psy-
chiatric disorders and cognitive decline can be a signiﬁ  cant 
morbidity in the aging HIV-infected patient.
Adherence issues
In HIV therapy, medication adherence is a very important 
determinant for the success or failure of treatment (DHHS 
2008). Unlike medication therapy for other disease states, 
medication nonadherence in HIV also creates multi-drug 
resistant HIV which further compromises treatment options. 
Antiretroviral adherence studies indicate that greater than 
95% adherence to ARV therapy provides optimal efﬁ  cacy 
while limiting viral rebound and development of HIV drug 
resistance, although at least 80% adherence has been used 
conventionally in non-HIV medication adherence studies 
(Bangsberg et al 2000; Paterson et al 2000; Gross et al 2001; 
Maggiolo et al 2005). To achieve a more than 95% adherence 
rate, a patient cannot miss more than 1 dose per month of a 
once daily medication, or no more than 2 missed doses per 
month for a twice daily medication regimen. While some stud-
ies suggest that medication adherence may be improved in the 
older HIV-infected patient, substance abuse and cognitive dys-
function may contribute to poor adherence (Wutoh et al 2003; 
Hinkin et al 2004). Other factors that can adversely affect 
medication adherence in elderly patients, which also overlap 
with factors affecting medication adherence in HIV-infected 
Table 5 (Continued)
Drug Class Cardiovascular 
agents
Lipid lowering 
agents
Anti-
microbials
Anti-
histamines
Gastrointestinal 
agents
CNS agentsb Herbals Other
Lopinavir/ Flecanide Lovastatin Rifampin Astemizole Cisapride Pimozide St. John’s Wort Fluticasone
Ritonavir Propafenone Simvastatin Rifapentine Terfenadine Midazolam
Triazolam
Ergot alkaloids
Tipranavir/ Amiodarone Lovastatin Rifampin Astemizole Cisapride Pimozide St. John’s Wort Fluticasone
Ritonavir Bepridil Simvastatin Rifapentine Terfenadine Midazolam
Flecanide Triazolam
Propafenone Ergot alkaloids
Quinidine
Darunavir/ – Lovastatin Rifampin Astemizole Cisapride Pimozide – Carbamazepine
Ritonavir Simvastatin Rifapentine Terfenadine Midazolam Phenobarbital
Triazolam Phenytoin
Ergot alkaloids Fluticasone
Antiretrovirals: Entry inhibitor
Maraviroca,e – – Rifampin
Rifapentine
– – – St. John’s Wort –
Abbreviations: PPI, proton pump inhibitors; FDA, Food and Drug Administration; PIs, protease inhibitors;   ATV,   Atazanavir; FPV, Fosamprenavir; TPV, Tipranavir.
Notes: Drugs listed to the right should not be used with the corresponding antiretroviral drug listed in the left hand column; aAdapted from publicly available resource (DHHS 
2008); bCentral nervous system (CNS) agents includes neuroleptics and psychotropics; Midazolam may be used with caution for procedural sedation, otherwise extended 
concomitant use is contraindicated; cRifabutin may be used with Ritonavir-boosted Saquinavir; dConcomitant Voriconazole is contraindicated with Ritonavir doses  400mg 
BID; eSelzentry PI 2007.Clinical Interventions in Aging 2008:3(3) 468
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persons, include: complex drug regimens (such as frequent 
dosing, large quantities of pills, and dietary restrictions) and 
increasing number of prescription medications; increasing 
number of prescribers (especially for patients seeing general-
ists and multiple specialists for various medical conditions); 
high medication costs; differing health beliefs (such as self-
efﬁ  cacy or belief in powerful others, eg, health care providers, 
who control a person’s well-being); medication side effects 
(including fear of experiencing side effects); lack of social 
support and living alone; psychiatric conditions (including 
depression), and cognitive and physical impairments (Wutoh 
et al 2003; Hughes 2004; Schlenk et al 2004).
Polypharmacy in the older patient is especially concern-
ing, since this patient population is also more likely to have 
chronic medical conditions for which multiple medications 
may be prescribed. The average number of prescriptions ﬁ  lled 
annually among noninstitutionalized Medicare enrollees 65 
years and older increased from 18 prescriptions in 1992 to 32 
prescriptions in 2002 (FIARS 2006). Furthermore, the num-
ber of prescriptions ﬁ  lled annually in this population ranged 
from an average of 11 prescriptions in those without any 
chronic medical conditions to an average of 61 prescriptions 
in persons with 5 or more chronic conditions. HIV medica-
tions will add at a minimum 3 additional medications (1–3 
prescriptions per month). If antimicrobials for OI prophylaxis 
or medications to manage HIV medication side effects are 
required, then an additional 2–5 medications per month over 
and above other medications for chronic conditions and HIV 
treatment may be required.
Assessment of medication adherence or nonadherence is 
essential in HIV therapy, as this information can be correlated 
with response to antiretroviral therapy as well as be used to 
identify areas for intervention and for providing focused patient 
counseling and support. Of note, health care providers were 
found to be poor predictors of patient medication adherence, 
misjudging adherence in 30% to 41% patients in one study 
(Paterson et al 2000). Thus, it is beneﬁ  cial to utilize various 
strategies in determining medication adherence, including 
reviewing pharmacy reﬁ  ll records and conducting focused 
patient medication adherence interviews. As opposed to ask-
ing closed-ended questions that can be answered by either a 
“yes” or “no” reply (eg, Did you miss any doses of your HIV 
medications?), open-ended questions can elicit more speciﬁ  c 
responses (eg, How many doses of your HIV medications have 
you missed in the past 2 weeks? In the past month?). In addi-
tion, it is equally important to assess reasons for medication 
nonadherence, such as medication side effects or pill fatigue, so 
that a patient’s issues and concerns are addressed sooner rather 
than later. This information could also be used to guide the 
clinician’s next steps in managing HIV regimen failure. Medi-
cation adherence tools that can be utilized to improve medication
adherence include simplifying antiretroviral therapy, pill boxes, 
social support, and using cues and incorporating dosing into 
daily routines (eg, taking medications with meals).
Primary care issues
It is likely that older patients being seen for routine 
medical care by general internists, geriatricians, or family 
practitioners may be involved in case ﬁ  nding for HIV 
infection. Some of those patients will test positive for HIV 
infection. It is important for generalists to recognize certain 
signs and symptoms that may be suggestive of ongoing HIV 
infection. HIV testing in the elderly should be offered and 
counseling provided. HIV infection should be suspected and 
worked-up in patients with co-morbid conditions that can 
indicate an increased risk for HIV infection. Elderly patients 
who have chronic hepatitis B virus (HBV) or hepatitis C 
virus (HCV) infection, or recent history of STDs should 
have HIV screening performed, if not already done. If prior 
negative tests for HIV infection have been recorded, renewed 
testing should be performed in the event that ongoing risk 
factors are elicited during the visit. Although reactivation of 
VZV (herpes zoster or shingles) is relatively common in the 
older adult, multidermatomal disease or dissemination may 
be an indication for signiﬁ  cant immunosuppression possibly 
as a result of HIV infection. Reactivation of tuberculosis, 
recurrent herpes simplex (HSV) infections, gastrointestinal 
parasitosis, mucocutaneous candida and fungal infections 
or molluscum contagiosum may also indicate ongoing HIV 
infection. Abnormalities on physical exam that can point 
to an HIV diagnosis include facial seborrhea, angular che-
litis, thrush, gingivitis, aphthous ulcers, hairy leukoplakia 
of tongue (highly indicative), diffuse lymphadenopathy, 
hepatosplenomegaly, onychomycosis and other dermatophy-
toses. Laboratory abnormalities such as anemia, leukopenia 
(especially lymphopenia), thrombocytopenia, and elevated 
total protein, in the absence of other diagnoses, can also 
suggest HIV infection.
The approach to newly diagnosed HIV-infected patients 
requires an evaluation that includes an assessment for ongo-
ing sexual activity, medical co-morbidities, mental health 
issues, and substance abuse issues; complete hematology 
and chemistry proﬁ  les, CD4 cell count, HIV viral load, HIV 
resistance testing, and serology for hepatitis viruses, syphilis 
and other STDs; routine vaccinations (except for live vac-
cines) and screening for cervical and rectal abnormalities Clinical Interventions in Aging 2008:3(3) 469
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by examination and pap smears; and other routine cancer 
screening such as mammography and colonoscopy (Aberg 
et al 2004). Patients should also be assessed for willingness 
and ability to adhere to HIV medication regimens, their 
understanding of HIV infection, and risk and harm reduc-
tion education. HIV-infected patients are routinely seen 
every 3–4 months to assess HIV treatment effectiveness, 
medication side effects, and ongoing medical or psycho-
social concerns. In HIV patients who are doing well, many 
of these routine visits can be accomplished through their 
primary care providers. In those elderly patients with a more 
complicated HIV disease course (eg, ARV treatment failure 
with drug resistance, ongoing OI) care switches back to an 
HIV specialist.
It is also likely that the generalist will have to balance HIV 
care with management of other co-morbid conditions com-
monly associated with aging such as hypertension, diabetes, 
and hyperlipidemia. For hypertension, blood pressure goals 
should follow those of the US National High Blood Pressure 
Education Program Seventh Report of the Joint National 
Committee (JNC VII) or similar other national guidelines. 
Renal function should be monitored in patients on either 
concomitant diuretics or angiotensin-converting enzyme 
(ACE) inhibitors and Tenofovir. Because calcium channel 
blockers are metabolized through the CYP 3A4 enzyme to 
a signiﬁ  cant extent, they should be used with caution and 
dose titrated accordingly when co-administered with pro-
tease inhibitors. An additional recommendation exists for 
Diltiazem: Diltiazem dose should be decreased by 50% in 
patients also taking Atazanavir.
Treatment of diabetes in the HIV-infected patient should 
utilize the same treatment strategies and aim for similar 
blood glucose and HgbA1C goals as those established by the 
American Diabetes Association and other similar organiza-
tions. As discussed earlier in this review, long-term use of 
protease inhibitors can lead to insulin resistance and glucose 
intolerance. Thus, insulin sensitizers such as Metformin and 
thiazolidiones should be considered for the treatment of 
diabetes in HIV-infected patients as long as no contraindi-
cations exist. Consideration may also be given to switching 
the antiretroviral regimen from a protease inhibitor-based to 
a NNRTI-based regimen. If a protease inhibitor is used, or 
required based on viral resistance, then Atazanavir may be 
an option, as it is not expected to affect blood glucose levels 
to a very signiﬁ  cant degree when compared to other protease 
inhibitors. There are no speciﬁ  c contraindicated drug-drug 
interactions between antidiabetic medications and antiret-
rovirals, but additional monitoring may be necessary due to 
overlapping medication toxicities (eg, thiazolidiones/PI and 
liver toxicity, Metformin/NRTIs and lactic acidosis). Provid-
ers should also watch for potential drug-drug interactions 
between thiazolidiones and NNRTIs or protease inhibitors 
resulting in increased effects of the hypoglycemic agent and 
adjust dosages of the antidiabetic drug as needed.
Lipid goals in HIV-infected patients with hyperlipidemia 
should follow the goals set by the National Heart, Lung, and 
Blood Institute’s National Cholesterol Education Program 
Adult Treatment Panel III (ATP III) guidelines or similar 
guidelines. Since lipid lowering agents and antiretrovirals can 
cause hepatotoxicity, close monitoring of LFTs is advised. 
Providers should also keep in mind that two particular statin 
agents, Lovastatin and Simvastatin, are contraindicated 
when co-administrated with a protease inhibitor. Alternative 
statins with limited to no clinically signiﬁ  cant drug interac-
tions with PIs include Fluvastatin, Pravastatin, and low-dose 
Atorvastatin. Another potent statin option available for the 
management of hyperlipidemia in HIV-negative patients 
is Rosuvastatin. Because Rosuvastatin is not metabolized 
through CYP 3A4, it is not expected to have a signiﬁ  cant 
interaction with antiretroviral therapy such as protease 
inhibitors. Notably, two small pilot studies have found that 
Rosuvastatin levels were actually increased 1.5- to nearly 
5-fold when co-administered with Lopinavir/Ritonavir (van 
der Lee et al 2007; Kiser et al 2008). At this time no speciﬁ  c 
Rosuvastatin dose adjustment recommendations exist for 
concurrent administration with Lopinavir/Ritonavir or other 
protease inhibitors, and until additional efﬁ  cacy and safety 
information becomes available, caution should be used with 
this combination in HIV-infected patients on HAART.
End of life issues
End of life care is not necessarily any different in the 
HIV-infected older person than in a younger person with 
HIV/AIDS or in the uninfected elderly. HIV-infected elderly 
patients with advanced HIV disease may not wish to dis-
close their diagnosis to family members or friends and thus 
may experience fear of abandonment and isolation. Some 
caregivers or family members may be concerned about the 
infectious nature of caring for an HIV-infected person who 
is dying and limit their contact as a consequence. Financial 
considerations may result in the decision to forgo taking 
expensive HIV medications. Some elderly patients may be 
ill-prepared in coping with the diagnosis, because of late 
diagnosis and already advanced disease and other serious 
concomitant co-morbid conditions. In addition to other end 
of life issues that need to be discussed, providers will need Clinical Interventions in Aging 2008:3(3) 470
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to have discussions with end-stage elderly patients about 
continued HIV treatment, OI prophylaxis or treatment, and 
nutritional support in those with HIV-associated wasting 
syndrome. Palliative care programs, whether home-based 
or hospital-based, appear to offer beneﬁ  t in quality of life 
domains for end-stage AIDS patients (Harding et al 2005).
Conclusions
The course of the HIV epidemic has dramatically changed over 
the past three decades largely as a result of growing awareness, 
implementation of prevention strategies, and the availability of 
potent antiretroviral therapy, especially in developed countries. 
However, current epidemiologic data show changes in the 
demographics of the HIV population. As the HIV population 
ages and the rate of newly detected infections in the elderly 
rise, clinicians should be aware of the increasing need to bal-
ance HIV care and the management of co-morbid conditions 
commonly associated with aging. To date, no guidelines are 
available that speciﬁ  cally address the needs of the elderly 
HIV-infected patient. Additional research is urgently needed 
to better understand the impact of aging on the course of HIV 
infection, to develop and implement effective education and 
prevention measures, and to determine efﬁ  cacy and safety of 
antiretroviral therapy in the older HIV-infected patient.
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